Source comparison
Comparison: BPC-157 vs Standard Arthritis Interventions
BPC-157 Moderate (cytokine suppression) Strong (Type II collagen ↑47%, aggrecan ↑38% in controlled trials) Minimal (no hepatotoxicity or GI ulceration documented) Extensive animal models; human trials pending Subcutaneous, intraperitoneal, topical gel NSAIDs S
This comparison does not assign a generated winner or score.
- BPC-157
- Moderate (cytokine suppression)
- Strong (Type II collagen ↑47%, aggrecan ↑38% in controlled trials)
- Minimal (no hepatotoxicity or GI ulceration documented)
- Extensive animal models; human trials pending
- Subcutaneous, intraperitoneal, topical gel
- NSAIDs
- Strong (COX inhibition)
- None (may accelerate cartilage loss long-term)
- GI bleeding, cardiovascular risk, renal impairment
- Extensive human clinical data
- Oral, topical
- Corticosteroid Injections
- Very strong (broad immune suppression)
- None (repeated use accelerates degeneration)
- Local: cartilage thinning, infection risk
- Well-established for symptom relief
- Intra-articular
- Hyaluronic Acid
- Minimal
- Minimal (viscosupplementation only)
- Low (local inflammation <5% of injections)
- Mixed evidence; efficacy debated
- PRP (Platelet-Rich Plasma)
- Moderate
- Moderate (growth factor delivery)
- Minimal (autologous tissue)
- Growing evidence in knee OA
- The comparison clarifies where BPC-157 studied arthritis research shows unique value: it's the only intervention in this table with documented cartilage regeneration in controlled trials without concurrent systemic toxicity. NSAIDs reduce pain but don't rebuild tissue. Corticosteroids suppress inflammation aggressively but worsen structural damage over time. PRP shows promise for regeneration but requires invasive preparation and repeated injections. BPC-157 demonstrates anabolic tissue effects with subcutaneous or even topical administration.